NasdaqCM:SLSBiotechs
SELLAS Life Sciences Group (SLS) Nears Key Phase 3 Readout On A Pricey Valuation
SELLAS Life Sciences Group (SLS) is drawing attention after its CEO highlighted that the pivotal Phase 3 REGAL trial for acute myeloid leukemia therapy Galinpepimut S is nearing final analysis, and institutional interest is also increasing.
See our latest analysis for SELLAS Life Sciences Group.
Against that backdrop, SELLAS Life Sciences Group’s recent news sits alongside strong share price momentum, with a 7 day share price return of 18.55% and a 90 day share price return of 46.04%. In...